% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Coronado:858397,
author = {Coronado, Monika Aparecida and Eberle, Raphael Josef and
Bleffert, Nicole and Feuerstein, Sophie and Olivier, Danilo
Silva and de Moraes, Fabio Rogerio and Willbold, Dieter and
Arni, Raghuvir Krishnaswamy},
title = {{Z}ika virus {NS}2{B}/{NS}3 proteinase: {A} new target for
an old drug - {S}uramin a lead compound for {NS}2{B}/{NS}3
proteinase inhibition-},
journal = {Antiviral research},
volume = {160},
issn = {0166-3542},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {FZJ-2018-07283},
pages = {118 - 125},
year = {2018},
abstract = {Zika virus infection is the focus of much research due to
the medical and social repercussions. Due the role of the
viral NS2B/NS3 proteinase in maturation of the viral
proteins, it had become an attractive antiviral target.
Numerous investigations on viral epidemiology, structure and
function analysis, vaccines, and therapeutic drugs have been
conducted around the world. At present, no approved vaccine
or even drugs have been reported. Thus, there is an urgent
need to develop therapeutic agents to cure this epidemic
disease. In the present study, we identified the polyanion
suramin, an approved antiparasitic drug with antiviral
properties, as a potential inhibitor of Zika virus complex
NS2B/NS3 proteinase with IC50 of 47 μM. Using
fluorescence spectroscopy results we could determine a kd
value of 28 μM and had shown that the ligand does not
affect the thermal stability of the protein. STD NMR
spectroscopy experiments and molecular docking followed by
molecular dynamics simulation identified the binding
epitopes of the molecule and shows the mode of interaction,
respectively. The computational analysis showed that suramin
block the Ser135 residue and interact with the catalytically
histidine residue.},
cin = {ICS-6},
ddc = {610},
cid = {I:(DE-Juel1)ICS-6-20110106},
pnm = {553 - Physical Basis of Diseases (POF3-553)},
pid = {G:(DE-HGF)POF3-553},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30393012},
UT = {WOS:000451936000014},
doi = {10.1016/j.antiviral.2018.10.019},
url = {https://juser.fz-juelich.de/record/858397},
}